Journal of Clinical Oncology
Articles in this Issue
Investigation of the association of <i>CTRB2</i> exon 6 deletion with time to progression and overall survival in pancreatic ductal adenocarcinoma.
770 Background: Pancreatic ductal adenocarcinoma (PDAC) is associated with poor prognosis and limited treatment options. A 584 bp deletion in...
Current status and treatment outcomes of intraductal papillary mucinous carcinoma in Korea: A multi-center cohort study.
812 Background: The spectrum of intraductal papillary mucinous neoplasm (IPMN) varies from benign cysts to intraductal papillary mucinous carcinoma (IPMC)...
Potential effect of the gut microbiome on tumour response to anti-cancer treatment in patients diagnosed with pancreatic ductal adenocarcinoma.
757 Background: Chemotherapy is the standard of care for pancreatic ductal adenocarcinoma (PDAC), however, recent research has identified bacteria in the...
Exploratory study of TAS-102 combined with intermittent administration of fruquintinib in the treatment of third-line metastatic colorectal cancer.
174 Background: Fruquintinib and TAS-102 are two globally recognized standard therapies for mCRC patients who have previously undergone standard chemother...
Risk of peritoneal recurrence following laparoscopic versus open surgery for stage II or III colorectal cancer (JCOG2310A): An integrated analysis of three phase III randomized controlled trials.
161 Background: Peritoneal recurrence in colorectal cancer (CRC) has long been a concern. Although studies have examined the higher risk of peritoneal rec...
Highly accurate detection of early-stage colorectal cancer using tumor and immune extracellular vesicles biomarkers.
262 Background: Colorectal cancer (CRC) is one of the most common cancers worldwide, and early detection is critical for successful treatment and improved...
Genetic differences in colorectal cancer across race and ethnicity.
28 Background: Colorectal cancer (CRC) is the fourth most common cause of cancer death and cancer-related mortality is expected to increase exponentially....
Use of pathological response versus RECIST assessment in predicting relapse-free survival following neoadjuvant immunotherapy for hepatocellular carcinoma.
633 Background: Immune checkpoint inhibitors (ICI) administered prior to liver resection (LR) lead to pathological responses in patients with hepatocellul...
Short-course radiotherapy-based total neoadjuvant therapy combined with tislelizumab in the treatment of locally advanced rectal cancer (Neo-STAR): Early outcomes of a prospective, randomized phase II trial.
150 Background: It has been found that radiotherapy possess synergistic anticancer effect with immune checkpoint inhibitors (ICIs). Therefore, this phase...
Effects of neighborhood deprivation index on survival in gastric cancers.
336 Background: Previous studies have shown that living in disadvantaged neighborhoods resulted in poor outcomes in several malignancies. Neighborhood Dep...
Short- and long-term outcomes of conversion surgery for initially unresectable advanced gastric cancer: A Japanese multicenter retrospective cohort study.
402 Background: The efficacy of conversion surgery in patients with unresectable advanced gastric cancer at the initial diagnosis who converted to be rese...
Effect of changes in body composition and sociodemographic factors on colon cancer survival.
296 Background: Muscle mass, muscle quality, and adipose tissue volumes have been shown to affect colon cancer survival. Further research is required to u...
Surufatinib combined with locoregional therapies and immune checkpoint inhibitor (ICI) for treating unresectable or metastatic intrahepatic cholangiocarcinoma.
593 Background: Advanced metastatic ICC, characterized by poor survival and limited therapeutic options, may benefit from the combined use of surufatinib—...
Clinical outcomes and changes in body composition following endoscopic submucosal dissection versus total gastrectomy in patients with proximal early gastric cancer.
415 Background: Sarcopenia is associated with poor surgical outcomes and prognosis in patients with gastric cancer. However, the relationship between chan...
Real-world microscopic residual disease (MRD) monitoring with circulating tumor DNA (ctDNA) in pancreatic adenocarcinoma (PDAC).
696 Background: ctDNA is a powerful tool that can detect MRD with limited but emerging data in patients (pts) with PDAC. We describe the clinical outcomes...
Spatially resolved protein profiling in pancreatic adenosquamous carcinoma.
760 Background: Pancreatic adenosquamous carcinoma (PASC) is a rare histopathological type of pancreatic cancer that is more aggressive than pancreatic du...
Birth cohort effects in appendiceal adenocarcinoma incidence across the United States.
90 Background: Appendiceal adenocarcinoma incidence rates are increasing across all age groups, sexes and histological subtypes in the United States. Birt...
AMBER part 2F: Cobolimab in combination with dostarlimab in treatment-naïve patients with locally advanced/metastatic and/or unresectable hepatocellular carcinoma (HCC).
TPS650 Background: The introduction of targeted treatment (tx) and immune checkpoint inhibitors (ICIs) has transformed the 1L advanced/metastatic (A/M) HC...
Gender imbalance in colon cancer screening rates in Texas: A population-based cohort study.
92 Background: Males have a higher risk of acquiring Colorectal Cancer (CRC) than females. In Texas, males are diagnosed with CRC more than females, regar...
Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
367 Background: Recently, PD-1 blockades combined with dual chemotherapy regimens in first-line setting exhibited encouraging efficacy for patients with E...
Non-metastatic gastric cancer (GC) in patients aged 80 years or older: Immediate and long-term outcomes of combined treatment.
453 Background: Comorbidities and increased risk of chemotherapy-induced toxicity in elderly patients presents significant challenges in management of GC....
Prevalence and clinical characteristics of patients with brain metastases at diagnosis with advanced hepatocellular carcinoma in a retrospective registry.
540 Background: Hepatocellular carcinoma (HCC) is a cancer with poor prognosis and rising incidence. The combination of atezolizumab plus bevacizumab (A+B...
Neoadjuvant chemoradiotherapy with ipilimumab and nivolumab in rectal cancer (CHINOREC): A prospective randomized, open-label, multicenter, phase II clinical trial.
139 Background: Immune checkpoint inhibitors (ICIs) seem only effective in a primed tumor immune microenvironment (TIME). Neoadjuvant radiotherapy (RT) ha...
Concordance between human epidermal growth factor receptor 2 (HER2) status by immunohistochemistry (IHC) and next-generation sequencing (NGS) in tissue and blood samples from gastric and gastroesophageal junction cancers (GC/GEJC).
478 Background: An estimated 18% of patients (pts) with GC/GEJC have HER2-positive (HER2+; IHC 3+ or 2+/in situ hybridization–positive [ISH+]) tumors. Alt...
Mediation of the liver protective effect of the anti-cancer drug candidate namodenoson via adiponectin.
604 Background: Namodenoson (CF102) is a small, orally available, anti-cancer drug candidate, currently in pivotal phase 3 clinical study for the treatmen...